Coherus Oncology (CHRS) Preferred Stock Liabilities (2012 - 2014)

Coherus Oncology has disclosed Preferred Stock Liabilities across 3 years of filings, most recently posting $161.2 million for Q3 2014.

• Preferred Stock Liabilities for Q3 2014 came in at $161.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2014 was $161.2 million (changed N/A YoY), and the FY2013 annual result was $54.7 million, up 993.9% from the prior year.
• Preferred Stock Liabilities came in at $161.2 million for Q3 2014 at Coherus Oncology, up from $54.7 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $161.2 million in Q3 2014 to a low of $5.0 million in Q4 2012.
• The 3-year median for Preferred Stock Liabilities is $54.7 million (2013), against an average of $73.6 million.
• Peak annual rise in Preferred Stock Liabilities reached 993.9% in 2013, while the deepest fall reached 993.9% in 2013.
• Coherus Oncology's Preferred Stock Liabilities stood at $5.0 million in 2012, then soared by 993.9% to $54.7 million in 2013, then jumped by 194.66% to $161.2 million in 2014.
• The last three Preferred Stock Liabilities figures came in at $161.2 million (Q3 2014), $54.7 million (Q4 2013), and $5.0 million (Q4 2012), per Business Quant data.